Major or minor Neurocognitive Disorders Neurocognitive disorders
Conditions
Interventions
Transcranial direct current stimulation
tDCS will be performed using a 1 by 1 low-intensity tDCS (Model 1300A
Soterix Medical Inc., New York, USA) that delivers direct current through two 35 cm2 electrodes. The anode electrode will be placed over the left dorsolateral prefrontal cortex, and the cathode will b
tDCS
Sponsors
Inagawa Takuma
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (a) subjects aged 55-90 years, with a diagnosis of either major neurocognitive disorder or mild neurocognitive disorder, as defined in DSM-5 (b) subjects taking a stable dose of psychotropic medications, such as cholinesterase inhibitors or NMDA (N-Methyl-D-aspartic acid) receptor antagonists, for the preceding two weeks prior to enrollment, or who do not take any psychotropic medications, cholinesterase inhibitors, or NMDA receptor antagonists. (c) subjects who are able to walk independently, with or without an aiding device (d) Benzodiazepines were allowed but were tapered to a maximum dose of 20 mg per day of a diazepam equivalent; the dose remained stable during the trial.
Exclusion criteria
Exclusion criteria: (a) subjects with severe psychotic symptoms requiring antipsychotic treatment (b) subjects requiring hospitalization within six weeks because of severe depression and/or suicidal ideation (c) subjects who have a clinical contraindication to electroconvulsive therapy or tDCS (d) subjects with an MMSE score of less than 18 or a Clinical Dementia Rating- Japan score of more than two (e) subjects who are unable to participate for more than two days during the trial (f) subjects who failed subsets (writing a sentence or copying a figure) in the MMSE at the time of screening. (g) subjects who are thought of as not adequate for participation by principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| between-group differences in mean ADAS-Cog from the baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| between-group differences in mean RBANS, MMSE, GDS, SF-36 from the baseline | — |
Contacts
Public ContactTakuma Inagawa
National center of neurology and psychiatry
Outcome results
None listed